Denne er kanskje kjent for flere, men litt spennende i disse tider
PhD student hos Pål Johansen , med støtte fra PCIB (TPCS2a)
In conclusion, liposomes could be successfully utilized to target B cells directly for stimulation of TI antibody responses and in a second strategy to target the MHC class-I pathway of antigen presentation for stimulation of CD8 T-cell responses. Hence, as a platform for antigen delivery, liposomes can serve very different purposes, for which reason liposomes may likely find utilization in variety of future vaccines or immunotherapies. For instance, TI vaccines may be proven beneficial for vaccination of immunosuppressed individuals, in conditions where T-cell activation has unwanted adverse effects, or during infectious outbreaks when rapid vaccination coverage and immune protection is needed. Furthermore, formulating photosensitizer in liposomes has the potential to bypass the default MHC class-II antigen presentation of vaccines antigens. The resulting stimulation of cytotoxic CD8 T-cell responses may find utilization in cancer immunotherapy or therapeutic vaccination against infections caused by intracellular pathogens that are not sensitive to and reached by antibodies. Finally, therapy intervals in ILIT affect the immunogenicity and treatment efficacy in mice and should be considered in clinical research and practice.
https://www.zora.uzh.ch/id/eprint/152755/1/152755.pdf